Breast cancer and the renin-angiotensin system (RAS): Therapeutic approaches and related metabolic diseases

Flávia Sardela de Miranda; João Pedro Tôrres Guimarães; Kalhara R Menikdiwela; Brennan Mabry; Rabin Dhakal; Rakhshanda Layeequr Rahman; Hanna Moussa; Naima Moustaid-Moussa

doi:10.1016/j.mce.2021.111245

Breast cancer and the renin-angiotensin system (RAS): Therapeutic approaches and related metabolic diseases

Mol Cell Endocrinol. 2021 May 15:528:111245. doi: 10.1016/j.mce.2021.111245. Epub 2021 Mar 20.

Authors

Flávia Sardela de Miranda¹, João Pedro Tôrres Guimarães², Kalhara R Menikdiwela¹, Brennan Mabry³, Rabin Dhakal⁴, Rakhshanda Layeequr Rahman⁵, Hanna Moussa⁶, Naima Moustaid-Moussa⁷

Affiliations

¹ Laboratory of Nutrigenomics, Inflammation and Obesity Research, Department of Nutritional Sciences, Texas Tech University (TTU), Lubbock, TX, USA; Obesity Research Institute, Texas Tech University, Lubbock, TX, USA.
² Laboratory of Nutrigenomics, Inflammation and Obesity Research, Department of Nutritional Sciences, Texas Tech University (TTU), Lubbock, TX, USA; Obesity Research Institute, Texas Tech University, Lubbock, TX, USA; Laboratory of Immunopharmacology, Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo (ICB/USP), São Paulo, SP, Brazil; Laboratory of Immunoendocrinology, Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo (FCF/USP), São Paulo, SP, Brazil.
³ Laboratory of Nutrigenomics, Inflammation and Obesity Research, Department of Nutritional Sciences, Texas Tech University (TTU), Lubbock, TX, USA.
⁴ Department of Mechanical Engineering, Texas Tech University (TTU), Lubbock, TX, USA.
⁵ Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
⁶ Obesity Research Institute, Texas Tech University, Lubbock, TX, USA; Department of Mechanical Engineering, Texas Tech University (TTU), Lubbock, TX, USA.
⁷ Laboratory of Nutrigenomics, Inflammation and Obesity Research, Department of Nutritional Sciences, Texas Tech University (TTU), Lubbock, TX, USA; Obesity Research Institute, Texas Tech University, Lubbock, TX, USA. Electronic address: Naima.moustaid-moussa@ttu.edu.

PMID: 33753205
DOI: 10.1016/j.mce.2021.111245

Abstract

The Renin-Angiotensin System (RAS) is classically recognized for regulating blood pressure and fluid balance. Recently, this role has extended to other areas including inflammation, obesity, diabetes, as well as breast cancer. RAS components are expressed in normal and cancerous breast tissues, and downregulation of RAS inhibits metastasis, proliferation, angiogenesis, and desmoplasia in the tumor microenvironment. Therefore, RAS inhibitors (Angiotensin receptor blockers, ARBs, or angiotensin converting enzyme inhibitors, ACE-I) may be beneficial as preventive adjuvant therapies to thwart breast cancer development and improve outcomes, respectively. Given the beneficial effects of RAS inhibitors in metabolic diseases, which often co-exist in breast cancer patients, combining RAS inhibitors with other breast cancer therapies may enhance the effectiveness of current treatments. This review scrutinizes above associations, to advance our understanding of the role of RAS in breast cancer and its potential for repurposing of RAS inhibitors to improve the therapeutic approach for breast cancer patients.

Keywords: Breast cancer; Cancer therapy; Renin-angiotensin system.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Breast Neoplasms / drug therapy
Breast Neoplasms / metabolism*
Female
Gene Expression Regulation, Neoplastic / drug effects
Humans
Renin-Angiotensin System / drug effects*
Treatment Outcome

Substances

Antineoplastic Agents